<DOC>
	<DOCNO>NCT00276575</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Erlotinib everolimus may stop growth tumor cell block enzymes need cell growth . Bevacizumab everolimus may also block blood flow tumor . Giving everolimus erlotinib together bevacizumab may kill tumor cell . PURPOSE : This randomized phase I trial study side effect best dose erlotinib everolimus give together bevacizumab treat patient advance solid tumor .</brief_summary>
	<brief_title>Bevacizumab , Everolimus , Erlotinib Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate maximum tolerate dose ( MTD ) /recommended phase II regimen everolimus erlotinib hydrochloride give bevacizumab patient advance solid tumor . - Evaluate safety bevacizumab , everolimus , erlotinib hydrochloride patient . Secondary - Describe impact combination therapy dermal wound angiogenesis inhibition vascular endothelial growth factor receptor 1 ( VEGFR1 ) , mTOR/p70S6K , related marker granulation tissue . - Evaluate clinical activity ( partial response , complete response , stable disease &gt; 6 month ) associate regimen . OUTLINE : This dose-escalation study follow randomize study . - Part 1 : Patients receive bevacizumab IV day 1 15 oral everolimus oral erlotinib hydrochloride* daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts patient receive escalate dos everolimus escalate dos everolimus erlotinib hydrochloride* maximum tolerate dose ( MTD ) determine . Patients part 2 study treat MTD everolimus erlotinib hydrochloride . NOTE : *The first cohort patient receive bevacizumab everolimus MTD determine , subsequent cohort patient receive bevacizumab , everolimus , erlotinib hydrochloride - Part 2 : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral everolimus daily begin day 1 , oral erlotinib hydrochloride daily begin day 15 , bevacizumab IV every 2 week begin day 15 . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive oral erlotinib hydrochloride daily begin day 1 , oral everolimus daily begin day 15 , bevacizumab IV every 2 week begin day 15 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy Metastatic unresectable disease Standard curative palliative measure exist OR longer effective No CNS metastases No centrallylocated nonsmall cell lung cancer PATIENT CHARACTERISTICS : ECOG performance status 02 Leukocytes ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN ( 5 time ULN know hepatic metastasis ) Urine protein creatinine ratio ≤ 1.0 OR urine protein &lt; 1 g 24 hour urine collection Creatinine clearance ≥ 50 mL/min OR creatinine normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study 4 month study treatment stop No uncontrolled hypertriglyceridemia ( i.e. , fast serum triglyceride &gt; 350 mg/dL ) No uncontrolled hypercholesterolemia ( i.e. , fast serum cholesterol &gt; 300 mg/dL ) No poorly control hypertension ( i.e. , blood pressure &gt; 160/100 mm Hg ) No poorly control clinically significant atherosclerotic vascular disease No thrombosis within 6 month No venous thromboembolic event within 6 month No arterial thromboembolic event within 12 month No cerebrovascular accident transient ischemic attack past 12 month No myocardial infarction unstable angina past 12 month No clinically significant peripheral vascular disease past 12 month No New York Heart Association class IIIV congestive heart failure Atrial supraventricular tachycardia well control beta blocker calcium channel blocker allow Chronic pacemaker use allow No serious cardiac arrhythmia require medication No clinically significant cardiovascular disease No hemoptysis &gt; 1 tablespoon within 6 month No presence bleed diathesis No coagulopathy No presence significant gastrointestinal ( GI ) disorder would affect drug absorption No hemodynamically significant GI bleed No history intolerance bevacizumab , everolimus , erlotinib No major bleed event No ongoing active infection No psychiatric illness social situation would limit safety compliance study requirement No uncontrolled intercurrent illness PRIOR CONCURRENT THERAPY : No angioplasty cardiac vascular stenting within past 12 month No major surgery within past 28 day No investigational agent within past 28 day No chemotherapy cancer within past 21 day No biologic therapy cancer within past 21 day No radiation therapy cancer within past 21 day No hormonal therapy cancer within past 21 day No minor surgical procedure within past 14 day No concurrent antiplatelet agent aspirin &lt; 325 mg/day No use statin drug pravastatin atorvastatin Initiation blood pressure ( BP ) medication permit prior study entry provide BP &lt; 150/90 mm Hg 3 measurement one week ( study day 7 1 ) start treatment No concurrent grapefruit juice No concurrent therapeutic anticoagulation Prophylactic lowdose anticoagulation indwell catheter permit No concurrent administration follow drug : Nicardipine Verapamil Clotrimazole Fluconazole Itraconazole Ketoconazole Clarithromycin Erythromycin Troleandomycin Cisapride Metoclopramide Bromocriptine Cimetidine Danazol HIVprotease inhibitor ( e.g. , ritonavir , indinavir ) Hypericum perforatum ( St. John 's wort ) Carbamazepine Phenobarbital Phenytoin Diltiazem Rifabutin Rifapentine Rifampin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>